Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 543329 | NSE Symbol : WINDLAS | ISIN : INE0H5O01029 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
03-Feb-2025	11-Feb-2025	Quarterly Results	Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve To inter alia consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31 2024 Outcome of the Board Meeting held on February 11, 2025 Outcome of the Board Meeting Re-appointment of Mr. Hitesh Windlass as Managing Director and Mr. Manoj Kumar Windlass as Joint Managing Director (As Per BSE Announcement Dated on: 11/02/2025)
05-Nov-2024	12-Nov-2024	Quarterly Results	Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve Intimation for the Board Meeting scheduled to be held on Tuesday November 12 2024 Approval of unaudited financial results for the quarter and half year ended 30th September, 202 (As Per BSE Announcement Dated on 12.11.2024)
02-Aug-2024	13-Aug-2024	Quarterly Results	Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve A meeting of the Board of Directors of the Company is scheduled to be held on Tuesday August 13 2024 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter ended June 30 2024. approval of the Un-audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2024. Approval of un-audited standalone and consolidated financial results for the quarter ended June 30, 2024 (As Per BSE Announcement Dated on 13.08.2024)
10-May-2024	20-May-2024	Accounts	Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2024 inter alia to consider and approve approve the audited standalone and consolidated financial results for the quarter and year ended March 31 2024 and to consider recommendation of dividend if any amongst other routine matters. Outcome of the Board Meeting Re-appointment of Mr. Pawan Kumar Sharma as an Executive Director (As Per BSE Announcement Dated on 20/05/2024
30-Jan-2024	08-Feb-2024	Quarterly Results	Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve A meeting of the Board of Directors of the Company is scheduled to be held on Thursday February 8 2024 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31 2023. Financial Results for the quarter and nine months ended December 31, 2023. Unaudited Financial Results for the quarter and nine months ended December 31, 2023. (As Per BSE Announcement Dated on 08/02/2024)
30-Oct-2023	08-Nov-2023	Quarterly Results	Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve To inter alia consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended September 30 2023. Unaudited Financial Results for the quarter and half year ended September 30, 2023. Un-audited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2023 (As Per BSE Announcement dated on 08.11.2023)
31-Jul-2023	08-Aug-2023	Quarterly Results	Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2023 inter alia to consider and approve To inter alia to consider and approve the un-audited standalone and consolidated financial results for the Quarter ended June 30 2023. Approval of unaudited financial results etc. (As Per BSE Announcement dated on 08.08.2023)
28-Apr-2023	05-May-2023	Accounts	Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2023 inter alia to consider and approve To consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31 2023 and to consider recommendation of dividend if any amongst other routine matters. Outcome of Board Meeting Recommended a Dividend of Rs 4.00/- per Equity Share of face value of Rs. 5/- each. The said dividend, if declared by the Members of the Company at the ensuing Annual General Meeting (AGM), will be credited/despatched within three weeks of the conclusion of said AGM (As Per BSE Announcement dated on 05.05.2023)
30-Jan-2023	08-Feb-2023	Quarterly Results	Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 inter alia to consider and approve Notice is hereby given that pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday February 08 2023 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31 2022. Please be also advised that in accordance with Code of Conduct to Regulate Monitor and Report Trading by Designated Persons of the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the Trading Window of the Company is already closed from January 01 2023 and it shall reopen on February 11 2023. Outcome of the meeting of the Board of Directors of Windlas Biotech Limited ('the Company') in terms of Regulation 30 and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As per BSE Announcement Dated on 08/02/2023)
31-Oct-2022	08-Nov-2022	Quarterly Results	Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2022 inter alia to consider and approve Un-audited standalone and consolidated financial results for the quarter and half year ended September 30 2022 Quarterly Results & Buy Back of Shares (As Per BSE Bulletin Dated on 03.11.2022) Outcome of the meeting of the Board of Directors of Windlas Biotech Limited ('the Company') in terms of Regulation 30 and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As Per BSE Announcement Dated on 08.11.2022) Corrigendum to the Outcome of the Board Meeting dated November 08, 2022. related buy-back announcement (As Per BSE Announcement Dated on 09/11/2022)
25-Jul-2022	04-Aug-2022	Quarterly Results	Quarterly Results Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022 ,inter alia, to consider and approve to consider and approve the un-audited standalone and consolidated financial results for the quarter ended June 30, 2022 Approval of Un-audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2022 Un-audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2022 (As Per BSE Announcement Dated 04.08.2022)
05-May-2022	12-May-2022	Accounts	Audited Results Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2022 ,inter alia, to consider and approve To consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2022 and to consider recommendation of dividend, if any, amongst other routine matters. Windlas Biotech Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 12, 2022, inter alia, has recommended a Dividend of Rs. 3.50/- per Equity Share of face value of Rs. 5/- each (@70%). The said dividend, if declared by the Members of the Company at the ensuing Annual General Meeting (AGM), will be credited/despatched within three weeks of the conclusion of said AGM. Outcome of Board Meeting (As Per BSE Announcement dated on 12.05.2022)
25-Jan-2022	02-Feb-2022	Quarterly Results	Quarterly Results Financial Results for the Quarter and Nine Months ended December 31, 2021 Outcome of the Board Meeting (As Per BSE Announcement Dated on 02.02.2022)
25-Oct-2021	01-Nov-2021	Quarterly Results	Quarterly Results Un-audited Standalone and Consolidated Financial Results for the Quarter and half year ended September 30, 2021. (As per BSE Announcement Dated on 01/11/2021)
25-Aug-2021	08-Sep-2021	Quarterly Results	Quarterly Results Outcome of the Board Meeting (As per BSE Announcement Dated on 8/9/2021)

LOGIN HERE

Windlas Biotech Ltd

Board Meeting